The Human Microbiome: Scientists to Unveil Latest Disease Research on Functionality and the Next Step Towards Causation at San Diego Congress
Scientists from academia and research studying the human microbiome set to share their collective insight at the Human Microbiome Congress in San Diego, CA this February.
San Diego, CA, October 30, 2015 --(PR.com)-- Research directors, professors and project scientists from the University of California at San Diego, Harvard, Stanford Medicine, University of Pennsylvania, INRA, The Jackson Laboratory, Yale and Texas Children’s Hospital are amongst those leading sessions on their experiences of functionality and novel methodology to congress participants.
With the Human Microbiome Market expected to reach $658 million by 2023 from $294 million in 2019 growing at a CAGR of 22.3% during the forecast period (2019-2023), understanding the human microbiome and harnessing its actionable insight will revolutionize medicine. The potential of human microbiome research to accurately link and prevent infectious diseases has caught the attention of scientists, R&D, biotech and pharmaceutical companies all interested in turning insight into therapeutic products.
Pharmaceutical giants including Johnson & Johnson, Pfizer and AbbVie have already begun to invest in the sector, along with non-pharma players like Nestlé. Further, new gene sequencing technologies by companies such as Illumina, ThermoFisher and Pacific Biosciences have made it possible for scientists to study the microbiome and its ecosystem in detail.
“Looking to the future, I can imagine in 15 years’ time, the goal will be to look at a person’s microbes and ensure the right balance is there and make adjustments if necessary to keep that person in optimal health,” says Professor George Weinstock, Geneticist, Washington University.
However, the industry’s infancy is not its only hindrance to making microbiome research application into a reality: in addition to a general lack of collaboration between leaders in basic research, clinician and pharma, there is also a need for a common vocabulary between computational and experimental scientists.
The Human Microbiome Congress positions itself as a neutral platform on which the different parties involved in the microbiome ecosystem can learn from and network with each other in order to holistically streamline knowledge from clinical trial to patient care. Combining networking sessions with plenary, roundtable and poster sessions, the event program covers a range of topics including the role of the microbiome in pregnancy, reproductive health, cystic fibrosis and its causal connections to disease.
The Human Microbiome Congress will take place from 10-11 February 2016 at the Hilton Hotel in San Diego, CA. Complete event information is available online at www.humanmicrobiomecongress.com. Reduced rates are available for academics, students and post-doctoral researchers; conference pass fees will apply. Contact Kim Vigilia at kv@kisacoresearch.com for inquiries.
Kisaco Research, an events and conference company in London, also hosts the European Microbiome Congress taking place in London in November, which has a specific focus on functionality and collaborative partnerships.
With the Human Microbiome Market expected to reach $658 million by 2023 from $294 million in 2019 growing at a CAGR of 22.3% during the forecast period (2019-2023), understanding the human microbiome and harnessing its actionable insight will revolutionize medicine. The potential of human microbiome research to accurately link and prevent infectious diseases has caught the attention of scientists, R&D, biotech and pharmaceutical companies all interested in turning insight into therapeutic products.
Pharmaceutical giants including Johnson & Johnson, Pfizer and AbbVie have already begun to invest in the sector, along with non-pharma players like Nestlé. Further, new gene sequencing technologies by companies such as Illumina, ThermoFisher and Pacific Biosciences have made it possible for scientists to study the microbiome and its ecosystem in detail.
“Looking to the future, I can imagine in 15 years’ time, the goal will be to look at a person’s microbes and ensure the right balance is there and make adjustments if necessary to keep that person in optimal health,” says Professor George Weinstock, Geneticist, Washington University.
However, the industry’s infancy is not its only hindrance to making microbiome research application into a reality: in addition to a general lack of collaboration between leaders in basic research, clinician and pharma, there is also a need for a common vocabulary between computational and experimental scientists.
The Human Microbiome Congress positions itself as a neutral platform on which the different parties involved in the microbiome ecosystem can learn from and network with each other in order to holistically streamline knowledge from clinical trial to patient care. Combining networking sessions with plenary, roundtable and poster sessions, the event program covers a range of topics including the role of the microbiome in pregnancy, reproductive health, cystic fibrosis and its causal connections to disease.
The Human Microbiome Congress will take place from 10-11 February 2016 at the Hilton Hotel in San Diego, CA. Complete event information is available online at www.humanmicrobiomecongress.com. Reduced rates are available for academics, students and post-doctoral researchers; conference pass fees will apply. Contact Kim Vigilia at kv@kisacoresearch.com for inquiries.
Kisaco Research, an events and conference company in London, also hosts the European Microbiome Congress taking place in London in November, which has a specific focus on functionality and collaborative partnerships.
Contact
Kisaco Research
Kim Vigilia
00442036962920
www.kisacoresearch.com
Kim Vigilia
00442036962920
www.kisacoresearch.com
Contact
Categories